

# Francesco Cavalli

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/564622/francesco-cavalli-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

358  
citations

8  
h-index

18  
g-index

21  
ext. papers

468  
ext. citations

5  
avg, IF

3.48  
L-index

#	Paper	IF	Citations
18	Optimizing drug delivery in COPD: The role of inhaler devices. <i>Respiratory Medicine</i> , <b>2017</b> , 124, 6-14	4.6	97
17	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2016</b> , 40, 95-103	3.5	80
16	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. <i>Respiratory Medicine</i> , <b>2017</b> , 129, 189-198	4.6	38
15	Iron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage?. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2014</b> , 28, 35-40	3.5	32
14	HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 483-90	13.6	24
13	Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2014</b> , 31, 191-7	1.1	24
12	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Delivery</i> , <b>2020</b> , 17, 635-646	8	20
11	Nonintubated surgical biopsy of undetermined interstitial lung disease: a multicentre outcome analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2019</b> , 28, 744-750	1.8	12
10	Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2019</b> , 13, 1753466619888128	4.9	7
9	Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.6	5
8	Treatable Mechanisms in Asthma. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 111-121	4.5	5
7	Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 535	5.4	4
6	New Avenues for Phosphodiesterase Inhibitors in Asthma. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 291-302	3	4
5	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 49, 20-26	3.5	2
4	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. <i>Biologics: Targets and Therapy</i> , <b>2021</b> , 15, 363-374	4.4	2
3	Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits <b>2020</b> , 66-81		1
2	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile.. <i>Journal of Asthma and Allergy</i> , <b>2022</b> , 15, 565-577	3.1	1

- 1 CD71 Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1444-1446 10.2